New Evidence For Kisqali Secures Funding In England For Second-Line Use
Executive Summary
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
You may also be interested in...
Improved Discount Helps Lilly Secure English Funding For Verzenios
Verzenios is now the second CDK4/6 inhibitor for advanced breast cancer that can be used routinely on England’s National Health Service in patients in a second-line setting.
Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.